Skip to main content
. Author manuscript; available in PMC: 2015 Sep 11.
Published in final edited form as: Clin Cancer Res. 2015 Feb 27;21(11):2471–2479. doi: 10.1158/1078-0432.CCR-14-2332

Table 2.

Baseline patient and disease characteristics.

Characteristic
n (%)		 Anti-Hypertensive Agent(s) Users Anti-Hypertensive
Agent(s) Non-User
n=2466		 Total Cohort
n=4736
ASI Users
n=1487		 Other
n=783
Age at initiation of therapy
  < 65 years
  ≥ 65 years
871 (58.6%)
616 (41.4%)
447 (57.1%)
336 (42.9%)
1940 (78.7%)
526 (21.3%)
3258 (68.8%)
1478 (31.2%)
Sex
  Male
  Female
1025 (68.9%)
462 (31.1%)
523 (66.8%)
260 (33.2%)
1815 (73.6%)
651 (26.4%)
3258 (68.8%)
1478 (31.2%)
Race
  Caucasian
  Other
1192 (80.2%)
295 (19.2%)
583 (74.5%)
200 (25.5%)
1889 (76.6%)
577 (23.4%)
3664 (77.4%)
1072 (22.6%)
ECOG Performance Status
  0
  1
  2
  Unknown
891 (59.9%)
574 (38.6%)
16 (1.1%)
6 (0.4%)
384 (49.0%)
386 (49.3%)
8 (1.0%)
5 (0.6%)
1220 (49.5%)
1198 (48.6%)
36 (1.5%)
12 (0.5%)
2495 (52.7%)
2158 (45.6%)
60 (1.3%)
23 (0.5%)
Pathology
  Clear cell
  Non-clear cell
  Unknown
1356 (91.2%)
95 (6.4%)
36 (2.4%)
702 (89.7%)
55 (7.0%)
26 (3.3%)
2177 (88.3%)
187 (7.6%)
102 (4.1%)
4235 (89.4%)
337 (7.1%)
164 (3.5%)
Baseline metastatic site
  Lung
  Bone
  Liver
1145 (77.0%)
363 (24.4%)
350 (23.5%)
597 (76.2%)
206 (26.3%)
210 (26.8%)
1887 (76.5%)
732 (29.7%)
678 (27.5%)
3629 (76.6%)
1301 (27.5%)
1238 (26.1%)
Previous nephrectomy
  Yes
  No
  Unknown
1096 (73.7%)
351 (23.6%)
40 (2.7%)
581 (74.2%)
168 (21.5%)
34 (4.3%)
1648 (66.8%)
688 (27.9%)
130 (5.3%)
3325 (70.2%)
1207 (25.5%)
204 (4.3%)
Prior type of therapy
  Any prior therapy
  Cytokine therapy
  Targeted therapy
529 (35.6%)
200 (13.4%)
220 (14.8%)
274 (35.0%)
111 (14.2%)
124 (15.8%)
770 (31.2%)
360 (14.6%)
229 (9.3%)
1573 (33.2%)
671 (14.2%)
573 (21.1%)
Medical Conditions
  Hypertension
  Diabetes mellitus
1250 (84.1%)
347 (23.3%)
634 (81.0%)
116 (14.8%)
383 (15.5%)
197 (8.0%)
2267 (47.9%)
660 (13.9%)

ECOG = Eastern Cooperative Oncology Group.